Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas

References

• Labreche K, Kinnersley B, Berzero G, et al. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathol. 2018;135(5):743–755.29460007
   PubMed Web of Science ®Google Scholar
• Pienkowski T, Kowalczyk T, Kretowski A, Ciborowski M. A review of gliomas-related proteins. Characteristics of potential biomarkers. Am J Cancer Res. 2021;11(7):3425–3444.34354853
   PubMed Web of Science ®Google Scholar
• van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010;120(3):297–304.20644945
   PubMed Web of Science ®Google Scholar
• Chen WJ, He DS, Tang RX, Ren FH, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015;16(2):411–420.25684464
   PubMedGoogle Scholar
• Jin Y, Xiao W, Song T, Feng G, Dai Z. Expression and prognostic significance of p53 in glioma patients: a meta-analysis. Neurochem Res. 2016;41(7):1723–1731.27038932
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508.26061753
   PubMed Web of Science ®Google Scholar
• Ammendola S, Caldonazzi N, Simbolo M, et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Arch. 2021. doi:10.1007/s00428-021-03134-1
   Web of Science ®Google Scholar
• Vuong HG, Altibi AMA, Duong UNP, et al. TERT promoter mutation and its interaction with IDH mutations in glioma: combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Crit Rev Oncol Hematol. 2017;120:1–9.29198322
   PubMed Web of Science ®Google Scholar
• Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014;5(6):1515–1525.24722048
   PubMed Web of Science ®Google Scholar
• Schulze Heuling E, Knab F, Radke J, et al. prognostic relevance of tumor purity and interaction with MGMT methylation in glioblastoma. Mol Cancer Res. 2017;15(5):532–540.28148826
   PubMed Web of Science ®Google Scholar
• Galbraith K, Snuderl M. Molecular pathology of gliomas. Surg Pathol Clin. 2021;14(3):379–386.34373090
   PubMedGoogle Scholar
• Hu X, Miao W, Zou Y, Zhang W, Zhang Y, Liu H. Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol Lett. 2013;6(1):130–134.23946790
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341–347.19435942
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–474.19554337
   PubMed Web of Science ®Google Scholar
• Labussière M, Di Stefano AL, Gleize V, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer. 2014;111(10):2024–2032.25314060
   PubMed Web of Science ®Google Scholar
• Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51.19997073
   PubMed Web of Science ®Google Scholar
• Yang P, Cai J, Yan W, et al. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016;18(8):1099–1108.26957363
   PubMed Web of Science ®Google Scholar
• Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):809–827.25943885
   PubMed Web of Science ®Google Scholar
• Yao J, Hagiwara A, Raymond C, et al. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Sci Rep. 2020;10(1):11922.32681084
   PubMed Web of Science ®Google Scholar
• Li YX, Shi Z, Aibaidula A, et al. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget. 2016;7(40):64615–64630.27556304
   PubMedGoogle Scholar
• Ballester LY, Huse JT, Tang G, Fuller GN. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results. Hum Pathol. 2017;69:15–22.28549927
   PubMed Web of Science ®Google Scholar
• Tabei Y, Kobayashi K, Saito K, et al. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status. Jpn J Clin Oncol. 2021;51(1):45–53.32888020
   PubMed Web of Science ®Google Scholar
• Ogura R, Tsukamoto Y, Natsumeda M, et al. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Neuropathology. 2015;35(4):324–335.25950388
   PubMed Web of Science ®Google Scholar
• Levidou G, El-Habr E, Saetta AA, et al. P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neuro-Oncol. 2010;100(3):363–371.
   PubMed Web of Science ®Google Scholar
• Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA. Ki-67 labeling index in glioblastoma; does it really matter? Hematol Oncol Stem Cell Ther. 2019;12(2):82–88.30552865
   PubMedGoogle Scholar
• Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985–1996.25053711
   PubMed Web of Science ®Google Scholar
• Diplas BH, He X, Brosnan-Cashman JA, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun. 2018;9(1):2087.29802247
   PubMed Web of Science ®Google Scholar